ProACT Adjustable Continence Therapy for Men
Uromedica, Inc. · Decision date Feb 11, 2026
What did the FDA decide?
FDA records P130018/S006 as a supplement to PMA P130018, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Feb 11, 2026.
FDA approval order statement
addition of a post-cure process to the manufacturing procedure for the implantable device component
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Feb 11, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P130018/S006
- Regulatory pathway
- PMA supplement
- Applicant
- Uromedica, Inc.
- Product code
- EZY
- Decision code
- OK30
- Decision date
- Feb 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Device, incontinence, mechanical/hydraulic.
- Applicant
- Uromedica, Inc.
- Product code
- EZY
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P130018/S004 · Related supplement
ProACT Adjustable Continence Therapy for Men
P130018/S006 received
Application receipt date recorded by FDA.
P130018/S005 · Related supplement
ProACT Adjustable Continence Therapy for Men
P130018/S006 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P130018. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P130018
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ProACT Adjustable Continence Therapy for MenP130018/S004 | Uromedica, Inc. | PMA supplement | Oct 3, 2025 | FDA |
ProACT Adjustable Continence Therapy for MenP130018/S005 | Uromedica, Inc. | PMA supplement | Jan 28, 2026 | FDA |
Explore the linked device profile
Other records with product code EZY
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
AMS 800 Artificial Urinary Sphincter (AUS)P000053/S142 | Boston Scientific Corp | PMA supplement | Sep 14, 2026 | FDA |
AMS 800 Artificial Urinary Sphincter (AUS)P000053/S141 | Boston Scientific Corp | PMA supplement | Feb 25, 2026 | FDA |
| Boston Scientific Corp | PMA approval | Jun 14, 2001 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Uromedica, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1840 Berkshire Ln. N., Plymouth, MN, 55441
Sources and methodology
- Original FDA record: P130018/S006
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



